Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable/recurrent esophageal squamous cell carcinoma.

Esophagus · 2025 · PMC12167336 · PMID 40274705

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

showed a trendP = 0.0970so close (0.05 < p ≤ 0.1)

The number of Foxp3 + lymphocytes per field showed a trend to an association with nivolumab response (15.3 with response vs. 38.0 with non-response, P = 0.0970).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.